Skip to main content
. Author manuscript; available in PMC: 2013 Jan 28.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 Jan 25;83(3):916–920. doi: 10.1016/j.ijrobp.2011.08.026

Table 5.

Summary of recent adjuvant clinical trial results in pancreatic cancer

Institution/Author n Median/5-year OS Local Failure Metastatic Disease
RTOG 9704 Regine et al. 451 20.5 months/22% (gemcitabine arm) 17.2 months/18% (5-FU arm) 28% (all patients) 73% (all patients)
CONKO-001 Oettle et al. 368 22.1 months/23% (gemcitabine arm) 20.2 months/11.5% (observation arm) 34% (gemcitabine) 41% (observation) 56% (gemcitabine) 49% (observation)
Johns Hopkins Herman et al. (9) 271 21.2 months/20.1% Not reported
Mayo Clinic Miller et al. (10) 269 25.2 months/28% Not reported

Abbreviations: OS = overall survival; RTOG = Radiation Therapy Oncology Group.